相关实验视频
Updated: Jan 13, 2026

11:10
Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
16.8K
在2型糖尿病患者服用葡萄糖类1受体激活剂的甲状腺癌风险
Bao Y Sciscent1, Hanel W Eberly1, F Jeffrey Lorenz1
1Department of Otolaryngology-Head and Neck Surgery Penn State Milton S. Hershey Medical Center and Penn State College of Medicine Hershey 17033 Pennsylvania USA.
OTO open
|January 12, 2026
概括
类似葡萄糖1受体激活剂 (GLP-1RA) 在2型糖尿病 (T2DM) 患者中没有增加甲状腺癌 (TC) 的5年风险. 这一发现与其他常见的糖尿病药物比较时是正确的,如甲福明和SGLT-2I.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类1受体激动剂 (GLP-1RA) 是有效的2型糖尿病 (T2DM) 血糖控制.
- 有关GLP-1RA使用与甲状腺癌 (TC) 之间可能存在关联的潜在担忧.
研究的目的:
- 在2型糖尿病 (T2DM) 患者中研究甲状腺癌 (TC) 的5年风险,这些患者接受了与葡萄糖类1受体激活剂 (GLP-1RA) 治疗.
主要方法:
- 使用TriNetX数据库进行了一项回顾性队列研究.
- 确定了2017-2019年2型糖尿病 (T2DM) 患者,并匹配了倾向性得分.
- 在GLP-1RA使用者中,甲状腺癌 (TC) 的5年风险与使用-葡萄糖共运输体2抑制剂 (SGLT-2I),甲福林和迪佩基酶4抑制剂 (DPP-4I) 的用户进行了比较.
主要成果:
- 在每位7736名患者的比较中,GLP-1RA用户的5年TC率为0.30%,而SGLT-2I用户的0.48% (RR为0.62).
- 对5158名患者的分析显示,GLP-1RA (0.25%) 和甲素 (0.39%) 用户之间的TC率相似.
- 在每位12570名患者的比较中,GLP-1RA使用者的TC率为0.33%,而DPP-4I使用者的TC率为0.37%,表明没有显著的增加.
结论:
- 使用GLP-1RA的2型糖尿病 (T2DM) 患者与使用甲胺,SGLT-2I或DPP-4I的患者相比,在5年内甲状腺癌 (TC) 的风险似乎没有增加.
- 由于大多数GLP-1RA药物的相对最近批准,长期结论有限.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
571
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Hypoglycemia and Glucagon
796
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
796
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Insulin: Dosing Regimen and Adverse Effects
670
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
670
Carbohydrate Metabolism
13.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.8K

